
AU  - McCoubrey, Hilary
C7  - pp. 316-324
TI  - Nutrition support in diabetes
SN  - 9780470670927
UR  - https://doi.org/10.1002/9781119121725.ch36
DO  - doi:10.1002/9781119121725.ch36
SP  - 316-324
KW  - blood glucose targets
KW  - diabetes
KW  - enteral nutrition
KW  - medication changes
KW  - oral nutritional supplements
KW  - parenteral nutrition
PY  - 2016
AB  - Summary Increasing numbers of diabetes inpatients across all hospital wards and specialities means that dietitians working in all areas need to have a good understanding of the guidelines for diabetes inpatients and how these apply to their particular patients? needs. In order to minimise impact on appetite for meals, oral nutrition supplements (ONS) are usually prescribed between meals, potentially resulting in extended periods when blood glucose concentrations maybe elevated. Exclusive enteral nutrition induces a more pronounced insulin and glucose response than solid, oral nutrition. Dietitians should be aware of appropriate insulin and medication regimes suited to different feeding rates and timings. Factors to be considered when planning nutritional support include individual nutritional requirements, gut absorption, suitability and tolerance of night-time enteral nutrition, and the need for breaks for procedures or other events. Current guidelines do not make full recommendation for management of patients requiring total parenteral nutrition (TPN).
ER  - 

TY  - JOUR
TI  - Author index: Proceedings
JO  - The Journal of Physiology
VL  - 473
IS  - index
SN  - 9780470670927
UR  - https://doi.org/10.1113/jphysiol.1993.sp019979
DO  - doi:10.1113/jphysiol.1993.sp019979
SP  - 201
EP  - 260
PY  - 1993
ER  - 

TY  - JOUR
TI  - International Society of Paediatric Oncology, SIOP XXXVIII Congress Meeting: Contents and Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 47
IS  - 4
SN  - 9780470670927
UR  - https://doi.org/10.1002/pbc.21044
DO  - doi:10.1002/pbc.21044
SP  - 355
EP  - 532
PY  - 2006
ER  - 

TY  - JOUR
TI  - 136th Annual Meeting Sunday, September 25, 2011 Poster Session Abstracts
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 70
IS  - S15
SN  - 9780470670927
UR  - https://doi.org/10.1002/ana.22579
DO  - doi:10.1002/ana.22579
SP  - S4
EP  - S79
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts of AGS/AFAR Posters
JO  - Journal of the American Geriatrics Society
JA  - Journal of the American Geriatrics Society
VL  - 39
IS  - 8
SN  - 9780470670927
UR  - https://doi.org/10.1111/j.1532-5415.1991.tb02724.x
DO  - doi:10.1111/j.1532-5415.1991.tb02724.x
SP  - A17
EP  - A77
PY  - 1991
ER  - 

TY  - JOUR
TI  - The Association of Paediatric Anaesthetists
JO  - Anaesthesia
VL  - 35
IS  - 11
SN  - 9780470670927
UR  - https://doi.org/10.1111/j.1365-2044.1980.tb05065.x
DO  - doi:10.1111/j.1365-2044.1980.tb05065.x
SP  - 1131
EP  - 1137
PY  - 1980
ER  - 

TY  - JOUR
TI  - Posters
JO  - Bipolar Disorders
VL  - 5
IS  - s1
SN  - 9780470670927
UR  - https://doi.org/10.1034/j.1399-5618.5.s1.12.x
DO  - doi:10.1034/j.1399-5618.5.s1.12.x
SP  - 27
EP  - 95
PY  - 2003
ER  - 

TY  - JOUR
AU  - Skagerlind, Malin
AU  - Stegmayr, Bernd
TI  - Heparin albumin priming in a clinical setting for hemodialysis patients at risk for bleeding
JO  - Hemodialysis International
JA  - Hemodialysis International
VL  - 21
IS  - 2
SN  - 9780470670927
UR  - https://doi.org/10.1111/hdi.12472
DO  - doi:10.1111/hdi.12472
SP  - 180
EP  - 189
KW  - Acute hemodialysis
KW  - anticoagulation
KW  - bleeding
KW  - priming
KW  - heparin
KW  - albumin
PY  - 2017
AB  - Abstract Introduction: Intermittent hemodialysis (IHD) is sometimes necessary in patients with a bleeding risk, i.e., before/after surgery or brain hemorrhage. In such case IHD has to be modified to limit the conventional anticoagulation used to avoid clotting of the extracorporeal circuit (ECC). We evaluated if priming using a heparin and albumin (HA) mixture could minimize the exposure to heparin. Methods: Retrospective data from 1995 to 2013 were collected from 1408 acute dialysis treatment protocols that included 321 patients. Comparisons were made between IHD patients that had increased risk for bleeding and were treated by standard anticoagulation (Group-S), and patients at increased risk of bleeding (Group-HA). The ECC in Group-HA was primed with a solution of unfractioned heparin (UFH) (5000 Units/L) and albumin (1 g/L) in saline that was discarded after priming. There were 16 different dialyzers in the material. Findings: Comparing Group-S (n?=?883) with Group-HA (n?=?221), the mean age was 61.6 vs. 62.2 years (P?=?0.8), dialysis time was 197 vs. 190 minutes (P?=?0.002), and total dose of intravenous anticoagulant/IHD was at median 5000 Units vs. 1200 Units (P?=?0.001). Twenty-four percent of patients were treated without any additional heparin. Clotting resulting in interrupted dialysis was similar in both groups (0.8% for Group-S vs. 1.0% for Group-HA, P?=?0.8). No secondary bleeding was reported in either group. Discussion: HA priming minimized the risk of clotting and enabled acute IHD in vulnerable patients without increased bleeding, thus allowing completion of IHD to the same extent as for standard HD.
ER  - 

TY  - JOUR
AU  - Preston, P. G.
TI  - A REVIEW OF 100 CASES OF TRANSPLANTATION OF THE URETERS IN THE TREATMENT OF OBSTETRICAL VESICOVAGINAL FISTULAE
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
VL  - 58
IS  - 2
SN  - 9780470670927
UR  - https://doi.org/10.1111/j.1471-0528.1951.tb04912.x
DO  - doi:10.1111/j.1471-0528.1951.tb04912.x
SP  - 282
EP  - 290
PY  - 1951
ER  - 

AU  - Owen, V. M.
C7  - pp. 431-450
TI  - Medical and Healthcare Sensors
SN  - 9783527267743
UR  - https://doi.org/10.1002/9783527620180.ch15
DO  - doi:10.1002/9783527620180.ch15
SP  - 431-450
KW  - biochemical
KW  - centralize
KW  - analysis
KW  - electrochemical
KW  - commercially
PY  - 1951
AB  - Summary The prelims comprise: Introduction Electrochemical Sensors Optical Sensors Biosensors Neural Activity Sensors Future Challenges Conclusion References
ER  - 

AU  - Dixon, Marjorie
AU  - MacDonald, Anita
AU  - White, Fiona
AU  - Stafford, Jacky
C7  - pp. 381-525
TI  - Disorders of Amino Acid Metabolism, Organic Acidaemias and Urea Cycle Disorders
SN  - 9780470659984
UR  - https://doi.org/10.1002/9781118915349.ch17
DO  - doi:10.1002/9781118915349.ch17
SP  - 381-525
KW  - amino acid disorders
KW  - homocystinuria (HCU)
KW  - maple syrup urine disease (MSUD)
KW  - metabolic processes
KW  - non dietetic treatment
KW  - organic acidaemias (OAA)
KW  - phenylketonuria (PKU)
KW  - tetrahydrobiopterin (BH4) deficiency
KW  - tyrosinaemia
KW  - urea cycle disorders (UCD)
PY  - 1951
AB  - Summary This chapter illustrates the metabolic processes involved in the overall metabolism of carbohydrates, fats and protein including the catabolic processes to produce energy and urea and anabolic processes to form tissue protein and energy stores, glycogen and lipids. It considers the following amino acid disorders: phenylketonuria (PKU) and tetrahydrobiopterin (BH4) deficiencies, maple syrup urine disease (MSUD), homocystinuria (HCU) and tyrosinaemia. For each condition, the prevalence, biochemistry, genetics, pathophysiology, diagnosis, outcome and non dietetic treatment is described separately. All these amino acid conditions share the same principles of dietary management. Therefore, the dietary management for all conditions is considered in the chapter. A low protein diet is an essential part of the management of organic acidaemias (OAA), e.g. isovaleric acidaemia (IVA), glutaric aciduria type 1 (GA1); and the urea cycle disorders (UCD). The chapter describes the provision of a low protein diet and acute management, common to these disorders.
ER  - 

TY  - JOUR
AU  - Beilin, L J
AU  - Bhattacharya, J
TI  - The effect of indomethacin on autoregulation of renal blood flow in the anasthetized dog.
JO  - The Journal of Physiology
VL  - 271
IS  - 3
SN  - 9780470659984
UR  - https://doi.org/10.1113/jphysiol.1977.sp012018
DO  - doi:10.1113/jphysiol.1977.sp012018
SP  - 625
EP  - 639
PY  - 1977
AB  - 1. Renal blood flow autoregulation was studied in anaesthetized greyhounds, using an electromagnetic flowmeter, before and after the administration of the prostaglandin-synthesis inhibitor, indomethacin, or phosphate buffer. 2. Indomethacin caused a reduction in renal blood flow at all levels of perfusion pressure, but did not affect the ability of the kidney to autoregulate. 3. The aburpt reinstatement of renal perfusion pressure from previously reduced levels caused a triphasic transient response in flow. Peak hyperaemia at the beginning of the transient was not affected by indomethacin. After indomethacin, the second phase of this flow transient showed an oscillatory pattern during which flow fell initially to levels significantly lower than control. 4. It is concluded that although indomethacin did not abolish steady-state autoregulation, renal prostaglandins may damp rapid oscillations in renal blood flow and thus contribute to the efficiency of autoregulation.
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Neurourology and Urodynamics
JA  - Neurourology and Urodynamics
VL  - 37
IS  - S1
SN  - 9780470659984
UR  - https://doi.org/10.1002/nau.23524
DO  - doi:10.1002/nau.23524
SP  - S518
EP  - S699
PY  - 2018
ER  - 

TY  - JOUR
TI  - Subject index
JO  - The Journal of Physiology
VL  - 473
IS  - index
SN  - 9780470659984
UR  - https://doi.org/10.1113/jphysiol.1993.sp019985
DO  - doi:10.1113/jphysiol.1993.sp019985
SP  - 501
EP  - 553
PY  - 1993
ER  - 

AU  - Owen, V. M.
C7  - pp. 431-450
TI  - Medical and Healthcare Sensors
SN  - 9783527265381
UR  - https://doi.org/10.1002/9783527619269.ch15g
DO  - doi:10.1002/9783527619269.ch15g
SP  - 431-450
KW  - biochemical
KW  - centralize
KW  - analysis
KW  - electrochemical
KW  - commercially
PY  - 1993
AB  - Summary The prelims comprise: Introduction Electrochemical Sensors Optical Sensors Biosensors Neural Activity Sensors Future Challenges Conclusion References
ER  - 

TY  - JOUR
TI  - Annual Meeting of the American Epilepsy Society New Orleans Louisiana, December 2–8, 1994
JO  - Epilepsia
VL  - 35
IS  - s8
SN  - 9783527265381
UR  - https://doi.org/10.1111/j.1528-1157.1994.tb02941.x
DO  - doi:10.1111/j.1528-1157.1994.tb02941.x
SP  - 1
EP  - 164
PY  - 1994
ER  - 

AU  - O'Donnell, Matthew D.
C7  - pp. 13-27
TI  - Melt-Derived Bioactive Glass
SN  - 9780470711613
UR  - https://doi.org/10.1002/9781118346457.ch2
DO  - doi:10.1002/9781118346457.ch2
SP  - 13-27
KW  - melt-derived bioactive glass
KW  - Bioglass® 45S5 bioactive glass, and the bonding with bones
KW  - synthetic bone grafts in orthopaedics, for periodontal use
KW  - Bioglass, Sensodyne Repair & Protect for tooth sensitivity
KW  - NovaMin, glass particles and ions raising pH
KW  - network connectivity, bioactivity
KW  - animal models, bioceramic efficacy in bone regeneration
KW  - bioactive glasses in personal care (Schott)
KW  - bioactive glasses, in hair straightening formulations (L'Oreal)
PY  - 1994
AB  - Summary This chapter contains sections titled: Bioglass Network Connectivity and Bioactivity Alternative Bioactive Glass Compositions In Vitro Studies In Vivo Studies and Commercial Products References
ER  - 

TY  - JOUR
TI  - Abstracts-part V (Continue in Part VI)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1992
IS  - S3
SN  - 9780470711613
UR  - https://doi.org/10.1002/mrmp.22419920307
DO  - doi:10.1002/mrmp.22419920307
SP  - 2411
EP  - 2921
PY  - 1992
ER  - 

TY  - JOUR
TI  - Abstracts from the 58th Annual Scientific Meeting American Headache Society
JO  - Headache: The Journal of Head and Face Pain
JA  - Headache: The Journal of Head and Face Pain
VL  - 56
IS  - S1
SN  - 9780470711613
UR  - https://doi.org/10.1111/head.12832
DO  - doi:10.1111/head.12832
SP  - 3
EP  - 83
PY  - 2016
ER  - 

TY  - JOUR
AU  - Meyer, J. S.
AU  - Hardebo, J. E.
TI  - EPILEPSY: HEADACHE: DEMENTIA
JO  - Acta Neurologica Scandinavica
VL  - 62
IS  - S74
SN  - 9780470711613
UR  - https://doi.org/10.1111/j.1600-0404.1980.tb05238.x
DO  - doi:10.1111/j.1600-0404.1980.tb05238.x
SP  - 119
EP  - 129
PY  - 1980
ER  - 
